{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:52:20Z","timestamp":1794577940819,"version":"4.9.1"},"reference-count":258,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,27]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The American Society of Hematology (ASH) guidelines on treatment of pediatric venous thromboembolism (VTE) were published in 2018. In the last 6 years, there has been a 10-fold increase in the number of children involved in VTE treatment trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The ASH Committee on Quality and Guidelines agreed to update the pediatric guidelines in conjunction with the International Society on Thrombosis and Haemostasis (ISTH). These ASH\/ISTH evidence-based guidelines are intended to support patients, clinicians, and other health care professionals in the management of pediatric patients with VTE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ASH\/ISTH formed a multidisciplinary guideline panel to minimize potential bias from conflicts of interest. An unconflicted patient representative was not identified. The University of Kansas Health System supported the guideline development process, updating or performing systematic evidence reviews up to 2024. The panel focused specifically on the 2018 questions for which there was the greatest amount of interim data. The panel used the GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The panel agreed on 20 recommendations and also provided implementation guidance on the optimal use of anticoagulants in pediatric patients. Key recommendations of these guidelines include the role of DOACs in the treatment of a variety of pediatric VTEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Further research is required. Key priorities are understanding the natural history of clinically unsuspected thrombosis across a range of patient subpopulations and obtaining real-world data on the use of DOACs in children.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015328","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T11:32:11Z","timestamp":1748345531000},"page":"2587-2636","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":93,"title":["American Society of Hematology\/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3970-8984","authenticated-orcid":false,"given":"Paul","family":"Monagle","sequence":"first","affiliation":[{"name":"1Departments of Paediatrics and Haematology, The University of Melbourne, Royal Children\u2019s Hospital, Murdoch Children\u2019s Research Institute, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2046-8343","authenticated-orcid":false,"given":"Muayad","family":"Azzam","sequence":"additional","affiliation":[{"name":"2Division of Nephrology, Department of Internal Medicine, Evidence-based Practice and Impact Center, The University of Kansas Health System, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6653-5946","authenticated-orcid":false,"given":"Rachel","family":"Bercovitz","sequence":"additional","affiliation":[{"name":"3Department of Pediatrics, Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children\u2019s Hospital of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6725-3035","authenticated-orcid":false,"given":"Marisol","family":"Betensky","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD"},{"name":"5Division of Hematology, Cancer and Blood Disorders Institute, Johns Hopkins All Children\u2019s Hospital, St. Petersburg, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukhmi","family":"Bhat","sequence":"additional","affiliation":[{"name":"3Department of Pediatrics, Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children\u2019s Hospital of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9986-4973","authenticated-orcid":false,"given":"Tina","family":"Biss","sequence":"additional","affiliation":[{"name":"6Department of Haematology, The Newcastle Upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4076-270X","authenticated-orcid":false,"given":"Brian","family":"Branchford","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Versiti Medical Science Institute, Wauwatosa, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7711-4530","authenticated-orcid":false,"given":"Leonardo R.","family":"Brand\u00e3o","sequence":"additional","affiliation":[{"name":"8Dalla Lana School of Public Health, University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1551-3995","authenticated-orcid":false,"given":"Anthony K. C.","family":"Chan","sequence":"additional","affiliation":[{"name":"9Department of Pediatrics, McMaster Children\u2019s Hospital, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6155-2691","authenticated-orcid":false,"given":"E. Vincent S.","family":"Faustino","sequence":"additional","affiliation":[{"name":"10Section of Critical Care, Department of Pediatrics, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1175-7266","authenticated-orcid":false,"given":"Julie","family":"Jaffray","sequence":"additional","affiliation":[{"name":"11Department of Pediatrics, Division of Hematology\/Oncology, University of California, San Diego, Rady Children\u2019s Hospital, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9272-6540","authenticated-orcid":false,"given":"Sophie","family":"Jones","sequence":"additional","affiliation":[{"name":"12Departments of Nursing and Haematology The University of Melbourne, Royal Children\u2019s Hospital, Murdoch Children\u2019s Research Institute, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3725-8485","authenticated-orcid":false,"given":"Hassan","family":"Kawtharany","sequence":"additional","affiliation":[{"name":"2Division of Nephrology, Department of Internal Medicine, Evidence-based Practice and Impact Center, The University of Kansas Health System, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1756-8271","authenticated-orcid":false,"given":"Bryce A.","family":"Kerlin","sequence":"additional","affiliation":[{"name":"13Department of Pediatrics, Nationwide Children\u2019s Hospital and The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4865-4033","authenticated-orcid":false,"given":"Nicole","family":"Kucine","sequence":"additional","affiliation":[{"name":"14Department of Pediatrics, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8004-4190","authenticated-orcid":false,"given":"Riten","family":"Kumar","sequence":"additional","affiliation":[{"name":"15Department of Pediatrics, Harvard Medical School, Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4989-6421","authenticated-orcid":false,"given":"Christoph","family":"Male","sequence":"additional","affiliation":[{"name":"16Department of Pediatrics, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2364-7205","authenticated-orcid":false,"given":"Marie-Claude","family":"Pelland-Marcotte","sequence":"additional","affiliation":[{"name":"17Department of Pediatrics, Centre Hospitalier Universitaire de Qu\u00e9bec, Centre M\u00e8re-Enfant, Qu\u00e9bec City, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8152-1040","authenticated-orcid":false,"given":"Leslie","family":"Raffini","sequence":"additional","affiliation":[{"name":"18Department of Pediatrics, Children\u2019s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7610-7214","authenticated-orcid":false,"given":"Chittalsinh","family":"Raulji","sequence":"additional","affiliation":[{"name":"19Department of Pediatrics, University of Nebraska Medical Center, Children\u2019s Hospital Nebraska, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2204-4568","authenticated-orcid":false,"given":"Sarah E.","family":"Sartain","sequence":"additional","affiliation":[{"name":"20Section of Hematology, Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Hospital, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2832-6884","authenticated-orcid":false,"given":"Clifford M.","family":"Takemoto","sequence":"additional","affiliation":[{"name":"21Department of Hematology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0283-9972","authenticated-orcid":false,"given":"Cristina","family":"Tarango","sequence":"additional","affiliation":[{"name":"22Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9036-039X","authenticated-orcid":false,"given":"C. Heleen","family":"van Ommen","sequence":"additional","affiliation":[{"name":"23Department of Pediatric Hematology, Erasmus Medical Center Sophia Children's Hospital, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9426-4075","authenticated-orcid":false,"given":"Maria C.","family":"Velez","sequence":"additional","affiliation":[{"name":"24Department of Pediatrics, Louisiana State University Health Sciences Center\/Children\u2019s Hospital New Orleans, New Orleans, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3448-0156","authenticated-orcid":false,"given":"Sara K.","family":"Vesely","sequence":"additional","affiliation":[{"name":"25Hudson College of Public Health, Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences, Oklahoma City, OK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5058-3596","authenticated-orcid":false,"given":"John","family":"Wiernikowski","sequence":"additional","affiliation":[{"name":"26Division of Hematology & Oncology, Department of Pediatrics, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9321-4301","authenticated-orcid":false,"given":"Suzan","family":"Williams","sequence":"additional","affiliation":[{"name":"27Division of Hematology\/Oncology, Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8904-3338","authenticated-orcid":false,"given":"Hope P.","family":"Wilson","sequence":"additional","affiliation":[{"name":"28Division of Pediatric Hematology\/Oncology, Department of Pediatrics, Children\u2019s of Alabama, The University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0921-0974","authenticated-orcid":false,"given":"Gary","family":"Woods","sequence":"additional","affiliation":[{"name":"29Department of Pediatrics, Emory University School of Medicine, Children\u2019s Healthcare of Atlanta, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3283-0415","authenticated-orcid":false,"given":"Ayesha","family":"Zia","sequence":"additional","affiliation":[{"name":"30Division of Hematology-Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2091-0875","authenticated-orcid":false,"given":"Reem A.","family":"Mustafa","sequence":"additional","affiliation":[{"name":"2Division of Nephrology, Department of Internal Medicine, Evidence-based Practice and Impact Center, The University of Kansas Health System, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"2025081313414483500_bib2","author":"Institute of Medicine","year":"2011"},{"issue":"7","key":"2025081313414483500_bib3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.7326\/0003-4819-156-7-201204030-00009","article-title":"Guidelines International Network: toward international standards for clinical practice guidelines","volume":"156","author":"Qaseem","year":"2012","journal-title":"Ann Intern Med"},{"issue":"7","key":"2025081313414483500_bib4","doi-asserted-by":"crossref","first-page":"548","DOI":"10.7326\/M14-1885","article-title":"Guidelines International Network: principles for disclosure of interests and management of conflicts in guidelines","volume":"163","author":"Sch\u00fcnemann","year":"2015","journal-title":"Ann Intern Med"},{"key":"2025081313414483500_bib5","doi-asserted-by":"crossref","first-page":"i2089","DOI":"10.1136\/bmj.i2089","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: clinical practice guidelines","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"2025081313414483500_bib6","doi-asserted-by":"crossref","first-page":"i2016","DOI":"10.1136\/bmj.i2016","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: introduction","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"issue":"7454","key":"2025081313414483500_bib7","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"Br Med J"},{"issue":"4","key":"2025081313414483500_bib8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"7650","key":"2025081313414483500_bib9","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"Br Med J"},{"issue":"7","key":"2025081313414483500_bib10","first-page":"677","article-title":"Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations","volume":"169","author":"Sch\u00fcnemann","year":"2003","journal-title":"CMAJ"},{"key":"2025081313414483500_bib11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jclinepi.2016.01.032","article-title":"GRADE guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health","volume":"76","author":"Sch\u00fcnemann","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"2025081313414483500_bib12","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1182\/blood.V83.5.1251.1251","article-title":"Venous thromboembolic complications (VTE) in children: first analyses of the Canadian registry of VTE","volume":"83","author":"Andrew","year":"1994","journal-title":"Blood"},{"key":"2025081313414483500_bib13","first-page":"OC422","article-title":"Thromboembolism in childhood: a prospective two year BPSU study in the United Kingdom. February 2001-February 2003","volume":"1","author":"Gibson","year":"2004","journal-title":"Br J Haematol"},{"issue":"5","key":"2025081313414483500_bib14","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1067\/mpd.2001.118192","article-title":"Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands","volume":"139","author":"van Ommen","year":"2001","journal-title":"J Pediatr"},{"issue":"4","key":"2025081313414483500_bib15","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1542\/peds.2009-0768","article-title":"Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007","volume":"124","author":"Raffini","year":"2009","journal-title":"Pediatrics"},{"issue":"3","key":"2025081313414483500_bib16","first-page":"24","article-title":"The continued rise of venous thromboembolism across US children's hospitals","volume":"149","author":"O'Brien","year":"2022","journal-title":"Pediatrics"},{"key":"2025081313414483500_bib17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.thromres.2017.11.019","article-title":"A multi-institutional registry of pediatric hospital-acquired thrombosis cases: the Children's Hospital-Acquired Thrombosis (CHAT) project","volume":"161","author":"Jaffray","year":"2018","journal-title":"Thromb Res"},{"issue":"7","key":"2025081313414483500_bib18","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/jth.12598","article-title":"Central venous catheter-related thrombosis and thromboprophylaxis in children: a systematic review and meta-analysis","volume":"12","author":"Vidal","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2025081313414483500_bib19","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1111\/jth.15732","article-title":"Diagnosis and management of severe congenital protein C deficiency (SCPCD): communication from the SSC of the ISTH","volume":"20","author":"Minford","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2025081313414483500_bib20","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.jtha.2023.01.019","article-title":"Corrigendum to diagnosis and management of severe congenital protein C deficiency (SCPCD): communication from the SSC of the ISTH [J Thromb Haemost. 2022 Jul;20(7):1735-1743]","volume":"21","author":"Minford","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2025081313414483500_bib44","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/blood.V97.4.858","article-title":"Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors","volume":"97","author":"Nowak-Gottl","year":"2001","journal-title":"Blood"},{"issue":"4","key":"2025081313414483500_bib45","doi-asserted-by":"crossref","first-page":"100174","DOI":"10.1016\/j.rpth.2023.100174","article-title":"Outcomes in infants with unprovoked venous thromboembolism: a retrospective cohort study","volume":"7","author":"Whitworth","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"2025081313414483500_bib79","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1538-7836.2012.04669.x","article-title":"A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis","volume":"10","author":"Rathbun","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"19","key":"2025081313414483500_bib46","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"2025081313414483500_bib80","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.chest.2021.09.019","article-title":"Acute management of high-risk and intermediate-risk pulmonary embolism in children: a review","volume":"161","author":"Ross","year":"2022","journal-title":"Chest"},{"issue":"6","key":"2025081313414483500_bib81","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"issue":"3","key":"2025081313414483500_bib82","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1097\/CCM.0000000000002921","article-title":"Pediatric in-hospital cardiac arrest secondary to acute pulmonary embolism","volume":"46","author":"Morgan","year":"2018","journal-title":"Crit Care Med"},{"issue":"3","key":"2025081313414483500_bib83","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1016\/S2352-3026(18)30224-2","article-title":"Outcomes and risk factors of massive and submassive pulmonary embolism in children: a retrospective cohort study","volume":"6","author":"Pelland-Marcotte","year":"2019","journal-title":"Lancet Haematol"},{"issue":"6","key":"2025081313414483500_bib21","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1203\/00006450-200006000-00013","article-title":"Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry","volume":"47","author":"Monagle","year":"2000","journal-title":"Pediatr Res"},{"issue":"3","key":"2025081313414483500_bib22","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/MOP.0000000000000084","article-title":"Venous thromboembolism in critically ill children","volume":"26","author":"Polikoff","year":"2014","journal-title":"Curr Opin Pediatr"},{"key":"2025081313414483500_bib23","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3389\/fped.2017.00198","article-title":"Pediatric hospital acquired venous thromboembolism","volume":"5","author":"Witmer","year":"2017","journal-title":"Front Pediatr"},{"issue":"1","key":"2025081313414483500_bib24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1472-6963-4-38","article-title":"Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches the GRADE Working Group","volume":"4","author":"Atkins","year":"2004","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"2025081313414483500_bib25","doi-asserted-by":"crossref","first-page":"E123","DOI":"10.1503\/cmaj.131237","article-title":"Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise","volume":"186","author":"Sch\u00fcnemann","year":"2014","journal-title":"CMAJ"},{"key":"2025081313414483500_bib26","author":"Institute of Medicine","year":"2009"},{"issue":"11","key":"2025081313414483500_bib27","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jclinepi.2014.05.006","article-title":"Considering intellectual, in addition to financial, conflicts of interest proved important in a clinical practice guideline: a descriptive study","volume":"67","author":"Akl","year":"2014","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"2025081313414483500_bib28","doi-asserted-by":"crossref","first-page":"738","DOI":"10.7326\/0003-4819-152-11-201006010-00254","article-title":"The vexing problem of guidelines and conflict of interest: a potential solution","volume":"152","author":"Guyatt","year":"2010","journal-title":"Ann Intern Med"},{"issue":"6","key":"2025081313414483500_bib29","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1164\/rccm.200901-0126ST","article-title":"An official American Thoracic Society policy statement: managing conflict of interest in professional societies","volume":"180","author":"Sch\u00fcnemann","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2025081313414483500_bib30","volume-title":"McMaster University and Evidence Prime","year":"2025"},{"issue":"4","key":"2025081313414483500_bib31","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","article-title":"GRADE guidelines: 2. Framing the question and deciding on important outcomes","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2025081313414483500_bib32","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jclinepi.2021.02.026","article-title":"GRADE notes: how to use GRADE when there is \"no\" evidence? A case study of the expert evidence approach","volume":"137","author":"Mustafa","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"2025081313414483500_bib33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12959-018-0182-4","article-title":"Clinical presentation and therapeutic management of venous thrombosis in young children: a retrospective analysis","volume":"16","author":"Chan","year":"2018","journal-title":"Thromb J"},{"issue":"4","key":"2025081313414483500_bib34","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jtha.2022.11.044","article-title":"NEOnatal Central-venous Line Observational study on Thrombosis (NEOCLOT): evaluation of a national guideline on management of neonatal catheter-related venous thrombosis","volume":"21","author":"van Ommen","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2025081313414483500_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26415","article-title":"Venous thromboembolism in pediatric trauma patients: ten-year experience and long-term follow-up in a tertiary care center","volume":"64","author":"Leeper","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2025081313414483500_bib36","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S2352-3026(19)30219-4","article-title":"Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial","volume":"7","author":"Male","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"2025081313414483500_bib37","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/S2352-3026(20)30368-9","article-title":"Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b\/3, non-inferiority trial","volume":"8","author":"Halton","year":"2021","journal-title":"Lancet Haematol"},{"issue":"7","key":"2025081313414483500_bib38","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1111\/jth.15731","article-title":"Recommendations for standardized definitions, clinical assessment, and future research in pediatric clinically unsuspected venous thromboembolism: communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis","volume":"20","author":"Betensky","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2025081313414483500_bib39","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2018-05-849737","article-title":"The natural history of asymptomatic central venous catheter\u2013related thrombosis in critically ill children","volume":"133","author":"Jones","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2025081313414483500_bib40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jama.2021.23182","article-title":"Effect of anticoagulant therapy for 6 weeks vs 3 months on recurrence and bleeding events in patients younger than 21 years of age with provoked venous thromboembolism: the Kids-DOTT randomized clinical trial","volume":"327","author":"Goldenberg","year":"2022","journal-title":"JAMA"},{"issue":"S1","key":"2025081313414483500_bib41","first-page":"119","article-title":"Single centre study on safety and efficacy of rivaroxaban in paediatric venous thromboembolism","volume":"201","author":"Hassan","year":"2023","journal-title":"Br J Haematol"},{"issue":"7","key":"2025081313414483500_bib42","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/MPH.0000000000000920","article-title":"Six weeks versus 3 months of anticoagulant treatment for pediatric central venous catheter-related venous thromboembolism","volume":"39","author":"Smith","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"2025081313414483500_bib43","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/bloodadvances.2020003635","article-title":"The ASH-ASPHO choosing wisely campaign: 5 hematologic tests and treatments to question","volume":"6","author":"O'Brien","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2025081313414483500_bib47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jtha.2022.11.031","article-title":"High rate of recurrent venous thromboembolism in children and adolescents with unprovoked venous thromboembolism","volume":"21","author":"Whitworth","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"24","key":"2025081313414483500_bib48","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1182\/bloodadvances.2020003244","article-title":"Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT)","volume":"4","author":"Connor","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"2025081313414483500_bib49","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1212\/CPJ.0000000000000720","article-title":"Treatment and outcome of childhood cerebral sinovenous thrombosis","volume":"10","author":"Felling","year":"2020","journal-title":"Neurol Clin Pract"},{"key":"2025081313414483500_bib50","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.pediatrneurol.2022.02.006","article-title":"Clinical profile and long-term outcomes in pediatric cavernous sinus thrombosis","volume":"130","author":"Karakas","year":"2022","journal-title":"Pediatr Neurol"},{"key":"2025081313414483500_bib51","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jpeds.2022.05.056","article-title":"Cerebral sinus venous thrombosis in infants after aurgery for congenital heart disease","volume":"248","author":"Harrar","year":"2022","journal-title":"J Pediatr"},{"issue":"3","key":"2025081313414483500_bib52","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00381-016-3329-2","article-title":"Pediatric cerebral sinovenous thrombosis following cranial surgery","volume":"33","author":"Petrov","year":"2017","journal-title":"Childs Nerv Syst"},{"issue":"3","key":"2025081313414483500_bib53","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.amjoto.2018.03.013","article-title":"The association between otogenic lateral sinus thrombosis and thrombophilia \u2013 a long-term follow-up","volume":"39","author":"Schneider","year":"2018","journal-title":"Am J Otolaryngol"},{"issue":"5","key":"2025081313414483500_bib54","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s13760-021-01807-x","article-title":"Pediatric cerebral sinus venous thrombosis: clinical characterization of a Portuguese cohort","volume":"122","author":"Rodrigues","year":"2022","journal-title":"Acta Neurol Belg"},{"key":"2025081313414483500_bib55","doi-asserted-by":"crossref","first-page":"111513","DOI":"10.1016\/j.ijporl.2023.111513","article-title":"Head and neck venous thrombosis secondary to pediatric otolaryngologic infection","volume":"168","author":"Engelhardt","year":"2023","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"2025081313414483500_bib56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejpn.2023.01.009","article-title":"Post traumatic cerebral sinovenous thrombosis in children: a retrospective and multicenter study","volume":"43","author":"Roth","year":"2023","journal-title":"Eur J Paediatr Neurol"},{"key":"2025081313414483500_bib57","doi-asserted-by":"crossref","first-page":"607776","DOI":"10.3389\/fped.2020.607776","article-title":"Analysis of 10 pediatric nephrotic syndrome cases with complications of cerebral sinovenous thrombosis","volume":"8","author":"Rong","year":"2020","journal-title":"Front Pediatr"},{"issue":"3","key":"2025081313414483500_bib58","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1161\/STR.0000000000000456","article-title":"Diagnosis and management of cerebral venous thrombosis: a scientific statement from the American Heart Association","volume":"55","author":"Saposnik","year":"2024","journal-title":"Stroke"},{"issue":"8","key":"2025081313414483500_bib59","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1001\/jamaneurol.2020.1022","article-title":"Effect of endovascular treatment with medical management vs standard care on severe cerebral venous thrombosis: the TO-ACT randomized clinical trial","volume":"77","author":"Coutinho","year":"2020","journal-title":"JAMA Neurol"},{"issue":"5","key":"2025081313414483500_bib60","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00467-020-04743-9","article-title":"Silent and dangerous: catheter-associated right atrial thrombus (CRAT) in children on chronic haemodialysis","volume":"36","author":"Garcia-Nicoletti","year":"2021","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"2025081313414483500_bib61","doi-asserted-by":"crossref","first-page":"102266","DOI":"10.1016\/j.rpth.2023.102266","article-title":"Intracardiac thrombi in pediatrics: anticoagulation approach and treatment outcomes","volume":"7","author":"Agarwal","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"11","key":"2025081313414483500_bib62","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1080\/14767058.2019.1647530","article-title":"Clinical features and treatment results in preterm infants with intracardiac thrombus","volume":"34","author":"Kara","year":"2021","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"1","key":"2025081313414483500_bib63","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/MBC.0000000000001100","article-title":"Assessment of clinical characteristics and treatment outcomes of pediatric patients with intracardiac thrombosis: a single-center experience","volume":"33","author":"Odaman Al","year":"2022","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"4","key":"2025081313414483500_bib64","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/MBC.0b013e3283333c7c","article-title":"Neonatal and childhood right atrial thrombosis: recognition and a risk-stratified treatment approach","volume":"21","author":"Yang","year":"2010","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"4","key":"2025081313414483500_bib65","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/MBC.0b013e32835b72d7","article-title":"Neonatal and childhood right atrial thrombosis: critical clot size","volume":"24","author":"Yang","year":"2013","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"9","key":"2025081313414483500_bib66","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1007\/s00467-023-05918-w","article-title":"Renal vein thrombosis in neonates: a case series of diagnosis, treatment and childhood kidney function follow-up","volume":"38","author":"Ndoudi Likoho","year":"2023","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"2025081313414483500_bib67","first-page":"2446","article-title":"Should we heparinise in neonatal renal vein thrombosis (RVT)? A single paediatric tertiary centre experience. IPNA 2022[abstract]","volume":"38","author":"Lim","year":"2023","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"2025081313414483500_bib68","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.pedneo.2017.09.009","article-title":"Spontaneous neonatal renal vein thromboses: should we treat them all? A report of five cases and a literature review","volume":"59","author":"Niada","year":"2018","journal-title":"Pediatr Neonatol"},{"issue":"4","key":"2025081313414483500_bib69","doi-asserted-by":"crossref","first-page":"e27572","DOI":"10.1002\/pbc.27572","article-title":"Outcomes following neonatal portal vein thrombosis: a descriptive, single-center study and review of anticoagulant therapy","volume":"66","author":"Bhatt","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"S2","key":"2025081313414483500_bib70","first-page":"e12591","article-title":"Portal vein thrombosis (PVT) in neonates and children: a ten-year prospective registry of a tertiary care single-centre in Argentina","volume":"5","author":"Cervio","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2025081313414483500_bib71","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12959-023-00508-0","article-title":"Neonatal portal vein thrombosis: risk factors, diagnosis, treatment recommendations and review of the literature","volume":"21","author":"Solgun","year":"2023","journal-title":"Thromb J"},{"key":"2025081313414483500_bib72","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.thromres.2021.01.010","article-title":"Temporal and anatomic relationship between superficial and deep vein thromboses in hospitalized children","volume":"200","author":"Doan","year":"2021","journal-title":"Thromb Res"},{"issue":"13","key":"2025081313414483500_bib73","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1056\/NEJMoa0912072","article-title":"Fondaparinux for the treatment of superficial-vein thrombosis in the legs","volume":"363","author":"Decousus","year":"2010","journal-title":"N Engl J Med"},{"issue":"14","key":"2025081313414483500_bib74","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/archinte.163.14.1657","article-title":"A pilot randomized double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis","volume":"163","author":"Superficial Thrombophlebitis Treated By Enoxaparin Study Group","year":"2003","journal-title":"Arch Intern Med"},{"issue":"3","key":"2025081313414483500_bib75","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2352-3026(17)30014-5","article-title":"Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial","volume":"4","author":"Beyer-Westendorf","year":"2017","journal-title":"Lancet Haematol"},{"issue":"11","key":"2025081313414483500_bib76","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1111\/jth.13478","article-title":"Incidence and risk factors of superficial and deep vein thrombosis associated with peripherally inserted central catheters in children","volume":"14","author":"Men\u00e9ndez","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2025081313414483500_bib77","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/jama.2014.520","article-title":"Treatment of lower extremity superficial thrombophlebitis","volume":"311","author":"Di Nisio","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"2025081313414483500_bib78","first-page":"672","article-title":"Treatment of superficial vein thrombosis to prevent deep vein thrombosis and pulmonary embolism: a systematic review","volume":"90","author":"Wichers","year":"2005","journal-title":"Haematologica"},{"issue":"3","key":"2025081313414483500_bib84","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1542\/hpeds.2019-0290","article-title":"Pediatric massive and submassive pulmonary embolism: a single-center experience","volume":"10","author":"Ross","year":"2020","journal-title":"Hosp Pediatr"},{"issue":"1","key":"2025081313414483500_bib85","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/jth.15548","article-title":"Symptomatic pulmonary embolus after catheter removal in children with catheter related thrombosis: a report from the CHAT Consortium","volume":"20","author":"Jaffray","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2025081313414483500_bib86","doi-asserted-by":"crossref","first-page":"338","DOI":"10.34172\/PS.2020.42","article-title":"Dabigatran versus warfarin for the treatment of pediatric thromboembolism: a pilot randomized trial","volume":"26","author":"Eghbali","year":"2020","journal-title":"Pharm Sci"},{"key":"2025081313414483500_bib87","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.thromres.2022.03.024","article-title":"Investigating the experience of parents who have given their infants enoxaparin at home","volume":"214","author":"Gilmore","year":"2022","journal-title":"Thromb Res"},{"issue":"5","key":"2025081313414483500_bib88","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/adc.2011.300085","article-title":"HEEADSSS assessment for adolescents requiring anticoagulation therapy","volume":"97","author":"Jones","year":"2012","journal-title":"Arch Dis Child"},{"issue":"2","key":"2025081313414483500_bib89","first-page":"320","article-title":"Control of heparin therapy. Sensitivity of the activated partial thromboplastin time for monitoring the antithrombotic effects of heparin","volume":"73","author":"Zucker","year":"1969","journal-title":"J Lab Clin Med"},{"issue":"7","key":"2025081313414483500_bib90","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1056\/NEJM197208172870703","article-title":"A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time","volume":"287","author":"Basu","year":"1972","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"2025081313414483500_bib91","doi-asserted-by":"crossref","first-page":"e737S","DOI":"10.1378\/chest.11-2308","article-title":"Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Monagle","year":"2012","journal-title":"Chest"},{"issue":"8","key":"2025081313414483500_bib92","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1111\/jth.15264","article-title":"APTT therapeutic range for monitoring unfractionated heparin therapy. Significant impact of the anti-Xa reagent used for correlation","volume":"19","author":"Toulon","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2025081313414483500_bib93","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.thromres.2006.10.006","article-title":"Monitoring unfractionated heparin (UFH) therapy: which anti-factor Xa assay is appropriate?","volume":"120","author":"Ignjatovic","year":"2007","journal-title":"Thromb Res"},{"issue":"3","key":"2025081313414483500_bib94","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0049-3848(77)90150-5","article-title":"Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III","volume":"10","author":"Teien","year":"1977","journal-title":"Thromb Res"},{"issue":"3","key":"2025081313414483500_bib95","doi-asserted-by":"crossref","first-page":"171","DOI":"10.5045\/br.2016.51.3.171","article-title":"Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy","volume":"51","author":"Byun","year":"2016","journal-title":"Blood Res"},{"issue":"7","key":"2025081313414483500_bib96","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/MPH.0000000000000966","article-title":"Activated partial thromboplastin time versus anti-factor Xa levels for monitoring unfractionated heparin therapy in children: an institutional experience","volume":"39","author":"Woods","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"issue":"6","key":"2025081313414483500_bib97","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.thromres.2005.11.004","article-title":"Age-related differences in heparin response","volume":"118","author":"Ignjatovic","year":"2006","journal-title":"Thromb Res"},{"issue":"10","key":"2025081313414483500_bib98","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1111\/j.1538-7836.2006.02136.x","article-title":"Therapeutic range for unfractionated heparin therapy: age-related differences in response in children","volume":"4","author":"Ignjatovic","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2025081313414483500_bib99","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00043426-199021000-00019","article-title":"Development of the hemostatic system in the neonate and young infant","volume":"12","author":"Andrew","year":"1990","journal-title":"Am J Pediatr Hematol Oncol"},{"issue":"5","key":"2025081313414483500_bib100","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1182\/blood.V72.5.1651.1651","article-title":"Development of the human coagulation system in the healthy premature infant","volume":"72","author":"Andrew","year":"1988","journal-title":"Blood"},{"issue":"1","key":"2025081313414483500_bib101","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1182\/blood.V70.1.165.165","article-title":"Development of the human coagulation system in the full-term infant","volume":"70","author":"Andrew","year":"1987","journal-title":"Blood"},{"issue":"18","key":"2025081313414483500_bib102","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1182\/blood-2015-06-651661","article-title":"Monitoring unfractionated heparin in children: a parallel-cohort randomized controlled trial comparing 2 dose protocols","volume":"126","author":"Hanslik","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2025081313414483500_bib103","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/jth.12890","article-title":"Retrospective cohort study comparing activated partial thromboplastin time versus anti-factor Xa activity nomograms for therapeutic unfractionated heparin monitoring in pediatrics","volume":"13","author":"Trucco","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2025081313414483500_bib104","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/01.mbc.0000164424.90545.6e","article-title":"Effects of pre-analytical variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation","volume":"16","author":"McGlasson","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"5","key":"2025081313414483500_bib105","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/bja\/aex044","article-title":"Pharmacokinetic\/pharmacodynamic model for unfractionated heparin dosing during cardiopulmonary bypass","volume":"118","author":"Delavenne","year":"2017","journal-title":"Br J Anaesth"},{"issue":"7","key":"2025081313414483500_bib106","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1203\/00006450-198107000-00007","article-title":"Heparin clearance in the newborn","volume":"15","author":"McDonald","year":"1981","journal-title":"Pediatr Res"},{"issue":"3","key":"2025081313414483500_bib107","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0022-3476(82)80086-3","article-title":"Anticoagulant therapy by continuous heparinization in newborn and older infants","volume":"101","author":"McDonald","year":"1982","journal-title":"J Pediatr"},{"issue":"1","key":"2025081313414483500_bib108","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1203\/00006450-199401000-00016","article-title":"Heparin therapy in pediatric patients: a prospective cohort study","volume":"35","author":"Andrew","year":"1994","journal-title":"Pediatr Res"},{"issue":"suppl 4","key":"2025081313414483500_bib109","doi-asserted-by":"crossref","first-page":"506S","DOI":"10.1378\/chest.108.4_Supplement.506S","article-title":"Antithrombotic therapy in children","volume":"108","author":"Michelson","year":"1995","journal-title":"Chest"},{"issue":"6","key":"2025081313414483500_bib110","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/j.1875-9114.2011.01049.x","article-title":"Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin","volume":"32","author":"Vandiver","year":"2012","journal-title":"Pharmacotherapy"},{"issue":"2","key":"2025081313414483500_bib111","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3324\/haematol.10616","article-title":"A clinically significant incidence of bleeding in critically ill children receiving therapeutic doses of unfractionated heparin: a prospective cohort study","volume":"92","author":"Kuhle","year":"2007","journal-title":"Haematologica"},{"issue":"4","key":"2025081313414483500_bib112","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/jth.12153","article-title":"Systematic review on heparin-induced thrombocytopenia in children: a call to action","volume":"11","author":"Avila","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2025081313414483500_bib113","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jpeds.2014.09.017","article-title":"Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system","volume":"166","author":"Obeng","year":"2015","journal-title":"J Pediatr"},{"issue":"1","key":"2025081313414483500_bib114","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.athoracsur.2004.07.002","article-title":"Incidence of heparin-induced thrombocytopenia and therapeutic strategies in pediatric cardiac surgery","volume":"79","author":"Boning","year":"2005","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"2025081313414483500_bib115","first-page":"358","article-title":"Prevalence of heparin-dependent platelet antibodies in children after cardiopulmonary bypass","volume":"8","author":"Hanson","year":"2007","journal-title":"Pediatr Crit Care Med"},{"issue":"1","key":"2025081313414483500_bib116","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1542\/peds.109.1.e10","article-title":"Heparin-induced thrombocytopenia-associated thrombosis in pediatric intensive care patients","volume":"109","author":"Schmugge","year":"2002","journal-title":"Pediatrics"},{"issue":"2","key":"2025081313414483500_bib117","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/0741-5214(92)90252-4","article-title":"Heparin-induced thrombocytopenia in the newborn","volume":"15","author":"Spadone","year":"1992","journal-title":"J Vasc Surg"},{"issue":"7","key":"2025081313414483500_bib118","doi-asserted-by":"crossref","first-page":"102214","DOI":"10.1016\/j.rpth.2023.102214","article-title":"Heparin-induced thrombocytopenia in newborns: experience at a pediatric hospital and a literature review","volume":"7","author":"Gay","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"2025081313414483500_bib119","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/ANC.0b013e3181afab5b","article-title":"Supporting staff recovery and reintegration after a critical incident resulting in infant death","volume":"9","author":"Roesler","year":"2009","journal-title":"Adv Neonatal Care"},{"issue":"3","key":"2025081313414483500_bib120","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/107602960200800309","article-title":"Osteoblast growth inhibition by unfractionated heparin and by low molecular weight heparins: an in-vitro investigation","volume":"8","author":"Kock","year":"2002","journal-title":"Clin Appl Thromb Hemost"},{"issue":"11","key":"2025081313414483500_bib121","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1161\/01.ATV.0000090671.56682.D7","article-title":"Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight","volume":"23","author":"Khorana","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"2025081313414483500_bib122","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1111\/j.1365-2222.2004.02129.x","article-title":"Heparin-induced recurrent anaphylaxis","volume":"34","author":"Berkun","year":"2004","journal-title":"Clin Exp Allergy"},{"issue":"suppl 2","key":"2025081313414483500_bib123","first-page":"30","article-title":"Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin","volume":"16","author":"Holm","year":"1986","journal-title":"Haemostasis"},{"issue":"9","key":"2025081313414483500_bib124","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1111\/j.1538-7836.2010.03964.x","article-title":"Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study","volume":"8","author":"Trame","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2025081313414483500_bib125","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/pbc.23396","article-title":"The impact of quality and duration of enoxaparin therapy on recurrent venous thrombosis in children","volume":"59","author":"Estepp","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"2025081313414483500_bib126","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1002\/pbc.26629","article-title":"Association of outcomes and anti-Xa levels in the treatment of pediatric venous thromboembolism","volume":"64","author":"Fan","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"2025081313414483500_bib127","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/01.mph.0000139453.22338.d9","article-title":"An assessment of published pediatric dosage guidelines for enoxaparin: a retrospective review","volume":"26","author":"Ho","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"issue":"1","key":"2025081313414483500_bib128","first-page":"43","article-title":"Utility of anti-xa monitoring in children receiving enoxaparin for therapeutic anticoagulation","volume":"10","author":"Leung","year":"2005","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"12","key":"2025081313414483500_bib129","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1111\/jth.13856","article-title":"Evaluation of the age-dependent dosing recommendations for the administration of daily tinzaparin in children with thrombosis","volume":"15","author":"Musgrave","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2025081313414483500_bib130","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1111\/jth.12716","article-title":"Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism","volume":"12","author":"O'Brien","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2025081313414483500_bib131","first-page":"689","article-title":"Evaluation of a pediatric enoxaparin dosing protocol and the impact on clinical outcomes","volume":"25","author":"Wiltrout","year":"2020","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"1","key":"2025081313414483500_bib132","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1538-7836.2008.03224.x","article-title":"Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time","volume":"7","author":"Cuker","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2025081313414483500_bib133","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/jth.12641","article-title":"Lack of anti-factor Xa assay standardization results in significant low molecular weight heparin (enoxaparin) dose variation in neonates and children","volume":"12","author":"Greene","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2025081313414483500_bib134","first-page":"e0053","article-title":"A pilot feasibility and safety multicenter trial of administering weight adjusted FiXED dose of low molecular weight heparin (ENOXAPARIN) to neonates and children with thrombosis","volume":"2","author":"Bhatt","year":"2021","journal-title":"Medicine"},{"issue":"7","key":"2025081313414483500_bib135","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.2019000998","article-title":"Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children","volume":"135","author":"Brandao","year":"2020","journal-title":"Blood"},{"issue":"17","key":"2025081313414483500_bib136","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1001\/jama.2022.3729","article-title":"Anticoagulant therapy for 6 weeks vs 3 months and recurrence and bleeding in patients younger than 21 years with provoked venous thromboembolism-reply","volume":"327","author":"Goldenberg","year":"2022","journal-title":"JAMA"},{"issue":"10","key":"2025081313414483500_bib137","doi-asserted-by":"crossref","first-page":"e500","DOI":"10.1016\/S2352-3026(19)30161-9","article-title":"Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies","volume":"6","author":"Monagle","year":"2019","journal-title":"Lancet Haematol"},{"issue":"2","key":"2025081313414483500_bib138","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/jcph.1716","article-title":"Population pharmacokinetic analysis of dalteparin in pediatric patients with venous thromboembolism","volume":"61","author":"Damle","year":"2021","journal-title":"J Clin Pharmacol"},{"issue":"suppl 2","key":"2025081313414483500_bib139","first-page":"43","article-title":"New frontiers with bemiparin: use in special populations","volume":"70","author":"Fontcuberta Boj","year":"2010","journal-title":"Drugs"},{"issue":"7","key":"2025081313414483500_bib140","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/MBC.0000000000001066","article-title":"Optimal dosing of bemiparin for deep vein thrombosis treatment in children: a retrospective study","volume":"32","author":"Garc\u00eda-Boyano","year":"2021","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"4","key":"2025081313414483500_bib141","doi-asserted-by":"crossref","first-page":"329","DOI":"10.5604\/15093492.1005092","article-title":"Clinical experience with the use of low molecular weight heparin in orthopaedic treatment of paediatric patients","volume":"14","author":"Latalski","year":"2012","journal-title":"Ortop Traumatol Rehabil"},{"issue":"6","key":"2025081313414483500_bib142","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.pharma.2021.02.007","article-title":"[Enoxaparin and tinzaparin in pediatrics: impact of recommendation on prescription quality and anti-Xa levels]","volume":"79","author":"Noailly","year":"2021","journal-title":"Ann Pharm Fr"},{"issue":"3","key":"2025081313414483500_bib143","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/PCC.0000000000000640","article-title":"Higher tinzaparin dosing is needed to achieve target anti-Xa levels in pediatric cardiac intensive care patients","volume":"17","author":"Roeleveld","year":"2016","journal-title":"Pediatr Crit Care Med"},{"issue":"3","key":"2025081313414483500_bib144","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/MPH.0b013e31816356f8","article-title":"Nadroparin therapy in pediatric patients with venous thromboembolic disease","volume":"30","author":"van Ommen","year":"2008","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"2025081313414483500_bib145","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s12247-022-09665-7","article-title":"Commercial low molecular weight heparins - patent ecosystem and technology paradigm for quality characterization","volume":"18","author":"Iqbal","year":"2022","journal-title":"J Pharm Innov"},{"issue":"3","key":"2025081313414483500_bib257","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000513784","article-title":"Dalteparin in newborn thrombosis, time for a new starting dose","volume":"118","author":"Steenman","year":"2021","journal-title":"Neonatology"},{"issue":"suppl 1","key":"2025081313414483500_bib146","doi-asserted-by":"crossref","first-page":"344S","DOI":"10.1378\/chest.119.1_suppl.344S","article-title":"Antithrombotic therapy in children","volume":"119","author":"Monagle","year":"2001","journal-title":"Chest"},{"issue":"1","key":"2025081313414483500_bib147","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1160\/TH08-03-0148","article-title":"Evaluation of enoxaparin dosing requirements in infants and children. Better dosing to achieve therapeutic levels","volume":"101","author":"Bauman","year":"2009","journal-title":"Thromb Haemost"},{"issue":"3","key":"2025081313414483500_bib148","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0022-3476(96)70273-1","article-title":"Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study","volume":"128","author":"Massicotte","year":"1996","journal-title":"J Pediatr"},{"issue":"11","key":"2025081313414483500_bib149","first-page":"e48830","article-title":"An evaluation of the appropriateness of initial enoxaparin dosing among pediatric patients","volume":"15","author":"Altuwayjiri","year":"2023","journal-title":"Cureus"},{"issue":"2","key":"2025081313414483500_bib150","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/MBC.0b013e32835b72b8","article-title":"Dosing and monitoring of enoxaparin therapy in children: experience in a tertiary care hospital","volume":"24","author":"Andrade-Campos","year":"2013","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"5","key":"2025081313414483500_bib151","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1177\/1076029613480557","article-title":"Evaluation of the use of low-molecular-weight heparin in neonates: a retrospective, single-center study","volume":"19","author":"Chander","year":"2013","journal-title":"Clin Appl Thromb Hemost"},{"issue":"2","key":"2025081313414483500_bib152","first-page":"128","article-title":"A critical evaluation of enoxaparin dose adjustment guidelines in children","volume":"24","author":"Dinh","year":"2019","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"4","key":"2025081313414483500_bib153","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0022-3476(00)90005-2","article-title":"The use of low molecular weight heparin in pediatric patients: a prospective cohort study","volume":"136","author":"Dix","year":"2000","journal-title":"J Pediatr"},{"issue":"2","key":"2025081313414483500_bib154","first-page":"119","article-title":"Effects of age and weight-based dosing of enoxaparin on anti-factor xa levels in pediatric patients","volume":"15","author":"Fung","year":"2010","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"5","key":"2025081313414483500_bib155","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2141.2010.08163.x","article-title":"Dosing and monitoring of enoxaparin (low molecular weight heparin) therapy in children","volume":"149","author":"Ignjatovic","year":"2010","journal-title":"Br J Haematol"},{"key":"2025081313414483500_bib156","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.blre.2018.06.003","article-title":"Are low-molecular-weight heparins safe and effective in children? A systematic review","volume":"33","author":"Klaassen","year":"2019","journal-title":"Blood Rev"},{"issue":"4","key":"2025081313414483500_bib157","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1111\/j.1651-2227.2011.02578.x","article-title":"Fluctuations of anti-Xa concentrations during maintenance enoxaparin therapy for neonatal thrombosis","volume":"101","author":"Lulic-Botica","year":"2012","journal-title":"Acta Paediatr"},{"issue":"9","key":"2025081313414483500_bib158","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1592\/phco.27.9.1263","article-title":"Enoxaparin use in the neonatal intensive care unit: experience over 8 years","volume":"27","author":"Malowany","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"6","key":"2025081313414483500_bib159","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.thromres.2007.11.009","article-title":"Enoxaparin for neonatal thrombosis: a call for a higher dose for neonates","volume":"122","author":"Malowany","year":"2008","journal-title":"Thromb Res"},{"issue":"1","key":"2025081313414483500_bib160","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1160\/TH08-03-0148","article-title":"Evaluation of enoxaparin dosing requirements in infants and children","volume":"101","author":"Bauman","year":"2009","journal-title":"Thromb Haemost"},{"issue":"3","key":"2025081313414483500_bib161","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1542\/peds.2004-0178","article-title":"Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant","volume":"114","author":"Michaels","year":"2004","journal-title":"Pediatrics"},{"issue":"6","key":"2025081313414483500_bib162","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/FTD.0000000000000435","article-title":"Enoxaparin population pharmacokinetics in the first year of life","volume":"39","author":"Moffett","year":"2017","journal-title":"Ther Drug Monit"},{"issue":"2","key":"2025081313414483500_bib163","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1177\/1060028017734234","article-title":"Population pharmacokinetics of enoxaparin in pediatric patients","volume":"52","author":"Moffett","year":"2018","journal-title":"Ann Pharmacother"},{"issue":"2","key":"2025081313414483500_bib164","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1017\/S1047951109990564","article-title":"Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit?","volume":"20","author":"Sanchez de Toledo","year":"2010","journal-title":"Cardiol Young"},{"issue":"7","key":"2025081313414483500_bib165","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1097\/PCC.0000000000000169","article-title":"Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children","volume":"15","author":"Schloemer","year":"2014","journal-title":"Pediatr Crit Care Med"},{"issue":"5","key":"2025081313414483500_bib166","doi-asserted-by":"crossref","first-page":"F365","DOI":"10.1136\/fn.88.5.F365","article-title":"Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients","volume":"88","author":"Streif","year":"2003","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"11","key":"2025081313414483500_bib167","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/ajhp\/zxz055","article-title":"Retrospective comparison of two enoxaparin dosing and monitoring protocols at a pediatric hospital","volume":"76","author":"Wolsey","year":"2019","journal-title":"Am J Health Syst Pharm"},{"issue":"7","key":"2025081313414483500_bib168","doi-asserted-by":"crossref","first-page":"e946","DOI":"10.1097\/MPH.0000000000002066","article-title":"Enoxaparin dose requirements to achieve therapeutic low-molecular-weight heparin anti-factor Xa levels in infants and young children","volume":"43","author":"Wysocki","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"issue":"6","key":"2025081313414483500_bib169","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.thromres.2008.09.001","article-title":"Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing","volume":"123","author":"Bauman","year":"2009","journal-title":"Thromb Res"},{"issue":"1","key":"2025081313414483500_bib170","first-page":"33","article-title":"Evaluation of enoxaparin dosing and monitoring in pediatric patients at Children's Teaching Hospital","volume":"20","author":"McCormick","year":"2015","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"9","key":"2025081313414483500_bib171","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/j.1538-7836.2007.02624.x","article-title":"Once-daily enoxaparin in pediatric thromboembolism: a dose finding and pharmacodynamics\/pharmacokinetics study","volume":"5","author":"O'Brien","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"12","key":"2025081313414483500_bib172","first-page":"1701","article-title":"Long-term safety and efficacy data on childhood venous thrombosis treated with a low molecular weight heparin: an open-label pilot study of once-daily versus twice-daily enoxaparin administration","volume":"91","author":"Schobess","year":"2006","journal-title":"Haematologica"},{"issue":"5","key":"2025081313414483500_bib173","doi-asserted-by":"crossref","first-page":"e655","DOI":"10.1097\/MPH.0000000000002601","article-title":"Once-daily compared with twice-daily enoxaparin maintenance therapy appears safe and efficacious in pediatric venous thromboembolism","volume":"45","author":"Gibson","year":"2023","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"2025081313414483500_bib174","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1097\/PCC.0000000000000049","article-title":"IV enoxaparin in pediatric and cardiac ICU patients","volume":"15","author":"Cies","year":"2014","journal-title":"Pediatr Crit Care Med"},{"issue":"6","key":"2025081313414483500_bib175","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/PCC.0b013e31818d1920","article-title":"Experience with intravenous enoxaparin in critically ill infants and children","volume":"9","author":"Crary","year":"2008","journal-title":"Pediatr Crit Care Med"},{"issue":"5","key":"2025081313414483500_bib176","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1097\/PCC.0000000000001126","article-title":"IV versus subcutaneous enoxaparin in critically ill infants and children: comparison of dosing, anticoagulation quality, efficacy, and safety outcomes","volume":"18","author":"Diab","year":"2017","journal-title":"Pediatr Crit Care Med"},{"issue":"5","key":"2025081313414483500_bib177","first-page":"456","article-title":"Intravenous enoxaparin in pediatric burn patients: a case series","volume":"24","author":"Streetz","year":"2019","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"5","key":"2025081313414483500_bib178","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1177\/1060028020955029","article-title":"Low-molecular-weight heparin and fondaparinux use in pediatric patients with obesity","volume":"55","author":"Garner","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"2","key":"2025081313414483500_bib179","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/cpt.2618","article-title":"Use of real-world data and physiologically-based pharmacokinetic modeling to characterize enoxaparin disposition in children with obesity","volume":"112","author":"Gerhart","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"2025081313414483500_bib180","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jpeds.2012.07.047","article-title":"Comparison of anti-Xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin","volume":"162","author":"Richard","year":"2013","journal-title":"J Pediatr"},{"issue":"12","key":"2025081313414483500_bib181","doi-asserted-by":"crossref","first-page":"5348","DOI":"10.1111\/bcp.15459","article-title":"Optimal dosing of enoxaparin in overweight and obese children","volume":"88","author":"Derbalah","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"2025081313414483500_bib182","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1016\/j.chest.2022.07.025","article-title":"Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline","volume":"162","author":"Douketis","year":"2022","journal-title":"Chest"},{"issue":"1","key":"2025081313414483500_bib183","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1046\/j.1365-2141.2002.03233.x","article-title":"Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin","volume":"116","author":"Crowther","year":"2002","journal-title":"Br J Haematol"},{"issue":"uppl 2","key":"2025081313414483500_bib184","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"issue":"6","key":"2025081313414483500_bib185","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/pbc.23011","article-title":"FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age","volume":"57","author":"Young","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"2025081313414483500_bib186","author":"Monagle","year":"2006","edition":"3rd ed"},{"issue":"3","key":"2025081313414483500_bib187","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1055\/s-0038-1642427","article-title":"Oral anticoagulation therpay in pediatric patients: a prospective study","volume":"71","author":"Andrew","year":"1994","journal-title":"Thromb Haemost"},{"issue":"1","key":"2025081313414483500_bib188","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ppedcard.2005.09.001","article-title":"Editorial","volume":"21","author":"Massicotte","year":"2005","journal-title":"Prog Pediatr Cardiol"},{"issue":"1","key":"2025081313414483500_bib189","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ppedcard.2005.09.013","article-title":"Evidence based recommendation for anticoagulation in children with congenital heart disease (primary prophylaxis: cardiac catheterization, mechanical heart valves, cardiac shunts, central lines and secondary prophylaxis: systemic thrombosis and stroke)","volume":"21","author":"Patricia Massicotte","year":"2005","journal-title":"Prog Pediatr Cardiol"},{"issue":"2","key":"2025081313414483500_bib190","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1023\/A:1008893706046","article-title":"Out-of-hospital coagulation monitoring and management","volume":"7","author":"Ansell","year":"1999","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"2025081313414483500_bib191","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s002460010078","article-title":"Capillary whole blood monitoring of oral anticoagulants in children in outpatient clinics and the home setting","volume":"21","author":"Marzinotto","year":"2000","journal-title":"Pediatr Cardiol"},{"issue":"3","key":"2025081313414483500_bib192","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1017\/S1047951101000282","article-title":"Self-management of oral anticoagulation in children with congenital heart disease","volume":"11","author":"Christensen","year":"2001","journal-title":"Cardiol Young"},{"issue":"9","key":"2025081313414483500_bib193","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood.V94.9.3007","article-title":"Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients","volume":"94","author":"Streif","year":"1999","journal-title":"Blood"},{"issue":"1","key":"2025081313414483500_bib194","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.thromres.2004.03.018","article-title":"Anticoagulation clinics for children achieve improved warfarin management","volume":"114","author":"Newall","year":"2004","journal-title":"Thromb Res"},{"issue":"2","key":"2025081313414483500_bib195","first-page":"199","article-title":"Anticoagulation with warfarin in pediatrics","volume":"26","author":"Desai","year":"2000","journal-title":"Pediatr Nurs"},{"issue":"4","key":"2025081313414483500_bib196","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/adc.2006.113886","article-title":"A comparative study of anticoagulant control in patients on long-term warfarin using home and hospital monitoring of the international normalised ratio","volume":"93","author":"Bradbury","year":"2008","journal-title":"Arch Dis Child"},{"issue":"5","key":"2025081313414483500_bib197","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1651-2227.2004.tb02998.x","article-title":"Oral anticoagulant treatment in children based on monitoring at home","volume":"93","author":"Mahonen","year":"2004","journal-title":"Acta Paediatr"},{"issue":"26","key":"2025081313414483500_bib198","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1182\/blood-2010-05-283861","article-title":"In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes","volume":"116","author":"Nowak-G\u00f6ttl","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2025081313414483500_bib199","first-page":"224","article-title":"Prediction of warfarin dose in pediatric patients: an evaluation of the predictive performance of several models","volume":"21","author":"Marek","year":"2016","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"8","key":"2025081313414483500_bib200","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1046\/j.1538-7836.2003.00256.x","article-title":"Acenocoumarol therapy in pediatric patients","volume":"1","author":"Bonduel","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2025081313414483500_bib201","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1160\/TH12-04-0242","article-title":"Phenprocoumon and acenocoumarol treatment in paediatric patients","volume":"108","author":"Spoor","year":"2012","journal-title":"Thromb Haemost"},{"issue":"suppl 2","key":"2025081313414483500_bib202","doi-asserted-by":"crossref","first-page":"e737S","DOI":"10.1378\/chest.11-2308","article-title":"Antithrombotic therapy in neonates and children","volume":"141","author":"Monagle","year":"2012","journal-title":"Chest"},{"issue":"9","key":"2025081313414483500_bib203","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/pbc.24546","article-title":"Readmissions for warfarin-related bleeding in pediatric patients after hospital discharge","volume":"60","author":"Moffett","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2025081313414483500_bib204","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.pcl.2017.08.004","article-title":"Anticoagulation therapies in children","volume":"64","author":"Young","year":"2017","journal-title":"Pediatr Clin North Am"},{"key":"2025081313414483500_bib205","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.thromres.2023.06.013","article-title":"Bleeding outcomes and management of supratherapeutic episodes secondary to warfarin in children: a single center 10-year experience","volume":"228","author":"Cohen","year":"2023","journal-title":"Thromb Res"},{"issue":"1","key":"2025081313414483500_bib206","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11239-017-1499-8","article-title":"Time in therapeutic range as a marker for thrombotic and bleeding outcomes in Fontan patients","volume":"44","author":"Faircloth","year":"2017","journal-title":"J Thromb Thrombolysis"},{"issue":"12","key":"2025081313414483500_bib207","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.clinthera.2021.09.021","article-title":"Real-world anticoagulant use and incidence of venous thromboembolism and major bleeding in children","volume":"43","author":"Hardin","year":"2021","journal-title":"Clin Ther"},{"issue":"13","key":"2025081313414483500_bib208","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/ajhp\/zxaa111","article-title":"Evaluation of dosing and safety outcomes of low-dose prophylactic warfarin in children after cardiothoracic surgery","volume":"77","author":"Harkin","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"2025081313414483500_bib209","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jjcc.2017.07.006","article-title":"Effects of home prothrombin international ratio (PT-INR) management in children with mechanical prosthetic valves \u2013 importance of individual correlations between laboratory and CoaguChek device PT-INRs","volume":"71","author":"Ino","year":"2018","journal-title":"J Cardiol"},{"issue":"1","key":"2025081313414483500_bib210","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/apa.14069","article-title":"Establishing a regional paediatric registry improved the overview and detection of side effects in children on anticoagulants","volume":"107","author":"Jeremiasen","year":"2018","journal-title":"Acta Paediatr"},{"issue":"8","key":"2025081313414483500_bib211","doi-asserted-by":"crossref","first-page":"102255","DOI":"10.1016\/j.rpth.2023.102255","article-title":"Guiding warfarin self-management in children: development of a warfarin nomogram","volume":"7","author":"Jones","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"2025081313414483500_bib212","doi-asserted-by":"crossref","first-page":"100066","DOI":"10.1016\/j.rpth.2023.100066","article-title":"Using an electronic medical record patient portal for warfarin self-management: empowering children and parents","volume":"7","author":"Jones","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2025081313414483500_bib213","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/jth.13897","article-title":"Characteristics and quality of oral anticoagulation treatment in pediatric patients in the Netherlands based on the CAPS cohort","volume":"16","author":"Maagdenberg","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2025081313414483500_bib214","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00246-022-02848-6","article-title":"Anticoagulation therapy after the Fontan procedure","volume":"43","author":"Miwa","year":"2022","journal-title":"Pediatr Cardiol"},{"issue":"1","key":"2025081313414483500_bib215","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11239-023-02806-w","article-title":"A regional anticoagulation program improves safety and outcomes for both children and adults","volume":"56","author":"Rodriguez","year":"2023","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"2025081313414483500_bib216","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40801-015-0056-z","article-title":"Traditional anticoagulants and hair loss: a role for direct oral anticoagulants? A review of the literature","volume":"3","author":"Watras","year":"2016","journal-title":"Drugs Real World Outcomes"},{"issue":"3","key":"2025081313414483500_bib217","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jamadermatol.2016.4821","article-title":"Warfarin-associated nonuremic calciphylaxis","volume":"153","author":"Yu","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"6","key":"2025081313414483500_bib218","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00246-014-0880-z","article-title":"Two cases of Warfarin-induced tracheobronchial calcification after Fontan surgery","volume":"35","author":"Eckersley","year":"2014","journal-title":"Pediatr Cardiol"},{"issue":"8","key":"2025081313414483500_bib219","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00247-013-2649-6","article-title":"Tracheobronchial calcifications in children","volume":"43","author":"Golding","year":"2013","journal-title":"Pediatr Radiol"},{"issue":"6","key":"2025081313414483500_bib220","doi-asserted-by":"crossref","first-page":"e787","DOI":"10.1097\/MJT.0000000000000961","article-title":"Warfarin-associated tracheobronchial calcification","volume":"26","author":"Kansara","year":"2019","journal-title":"Am J Ther"},{"issue":"4","key":"2025081313414483500_bib221","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jtcvs.2020.12.102","article-title":"Long-term outcomes of warfarin versus aspirin after Fontan surgery","volume":"162","author":"Attard","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"4","key":"2025081313414483500_bib222","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1203\/01.PDR.0000155943.07244.04","article-title":"Reduced bone density in children on long-term warfarin","volume":"57","author":"Barnes","year":"2005","journal-title":"Pediatr Res"},{"issue":"4","key":"2025081313414483500_bib223","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00246-014-1083-3","article-title":"Bone density in children with single ventricle physiology","volume":"36","author":"Bendaly","year":"2015","journal-title":"Pediatr Cardiol"},{"key":"2025081313414483500_bib224","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bcmd.2017.05.008","article-title":"Anticoagulation therapy in neonates, children and adolescents","volume":"67","author":"Hepponstall","year":"2017","journal-title":"Blood Cells Mol Dis"},{"issue":"21","key":"2025081313414483500_bib225","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.3390\/ijms20215275","article-title":"Anticoagulants and osteoporosis","volume":"20","author":"Signorelli","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2025081313414483500_bib226","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11239-015-1319-y","article-title":"Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism","volume":"41","author":"Witt","year":"2016","journal-title":"J Thromb Thrombolysis"},{"issue":"7","key":"2025081313414483500_bib227","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1001\/jamainternmed.2015.1843","article-title":"Bleeding, recurrent venous thromboembolism, and mortality risks during warfarin interruption for invasive procedures","volume":"175","author":"Clark","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"9","key":"2025081313414483500_bib228","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJMoa1501035","article-title":"Perioperative bridging anticoagulation in patients with atrial fibrillation","volume":"373","author":"Douketis","year":"2015","journal-title":"N Engl J Med"},{"issue":"13","key":"2025081313414483500_bib229","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1161\/CIRCULATIONAHA.112.105221","article-title":"Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates","volume":"126","author":"Siegal","year":"2012","journal-title":"Circulation"},{"issue":"5","key":"2025081313414483500_bib230","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1161\/CIRCULATIONAHA.114.011777","article-title":"Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)","volume":"131","author":"Steinberg","year":"2015","journal-title":"Circulation"},{"key":"2025081313414483500_bib231","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.thromres.2016.01.010","article-title":"Oral anticoagulant therapy interruption in children: a single centre experience","volume":"140","author":"Campbell","year":"2016","journal-title":"Thromb Res"},{"issue":"suppl 2","key":"2025081313414483500_bib232","doi-asserted-by":"crossref","first-page":"e152S","DOI":"10.1378\/chest.11-2295","article-title":"Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Holbrook","year":"2012","journal-title":"Chest"},{"issue":"8","key":"2025081313414483500_bib233","first-page":"e5484","article-title":"Pharmacokinetic properties of rivaroxaban in healthy human subjects","volume":"11","author":"Bratsos","year":"2019","journal-title":"Cureus"},{"issue":"1","key":"2025081313414483500_bib234","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2174\/1574884708666131111204658","article-title":"Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor","volume":"9","author":"Kreutz","year":"2014","journal-title":"Curr Clin Pharmacol"},{"issue":"10","key":"2025081313414483500_bib235","doi-asserted-by":"crossref","first-page":"e29888","DOI":"10.1002\/pbc.29888","article-title":"Rivaroxaban treatment among children with cancer-associated thromboembolism: real-world data","volume":"69","author":"Barg","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2025081313414483500_bib236","doi-asserted-by":"crossref","first-page":"100001","DOI":"10.1016\/j.rpth.2022.100001","article-title":"Direct oral anticoagulants in pediatric venous thromboembolism: experience in specialized pediatric hemostasis centers in the United States","volume":"7","author":"Corrales-Medina","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"11","key":"2025081313414483500_bib237","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jamainternmed.2019.2431","article-title":"Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant","volume":"179","author":"Douketis","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"14","key":"2025081313414483500_bib238","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"2025081313414483500_bib239","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1055\/s-0042-1744542","article-title":"Anticoagulant effects of dabigatran on coagulation laboratory parameters in pediatric patients: combined data from five pediatric clinical trials","volume":"122","author":"Mitchell","year":"2022","journal-title":"Thromb Haemost"},{"key":"2025081313414483500_bib240","unstructured":"Pradaxa, international non-proprietary name: dabigatran etexilate. European Medicines Agency. 12 November 2020. Accessed 30 April 2024. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/pradaxa-h-c-829-x-0122-g-epar-assessment-report-extension_en.pdf."},{"issue":"5","key":"2025081313414483500_bib241","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1160\/TH14-12-1080","article-title":"A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran","volume":"113","author":"Glund","year":"2015","journal-title":"Thromb Haemost"},{"issue":"24","key":"2025081313414483500_bib242","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1161\/01.cir.0000436140.77832.7a","article-title":"Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association","volume":"128","author":"Giglia","year":"2013","journal-title":"Circulation"},{"issue":"1","key":"2025081313414483500_bib243","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2006-12-061234","article-title":"A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children","volume":"110","author":"Goldenberg","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2025081313414483500_bib244","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MPH.0b013e3181cc826e","article-title":"Low-dose systemic thrombolytic therapy for deep vein thrombosis in pediatric patients","volume":"32","author":"Leary","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"issue":"5","key":"2025081313414483500_bib245","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00043426-200305000-00006","article-title":"Low-dose tissue plasminogen activator thrombolysis in children","volume":"25","author":"Wang","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"issue":"5897","key":"2025081313414483500_bib246","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/301214a0","article-title":"Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli","volume":"301","author":"Pennica","year":"1983","journal-title":"Nature"},{"issue":"6","key":"2025081313414483500_bib247","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1080\/08880018.2021.1889729","article-title":"Clinical characteristics and outcomes of combined thrombolysis and anticoagulation for pediatric and young adult lower extremity and inferior vena cava thrombosis","volume":"38","author":"Cohen","year":"2021","journal-title":"Pediatr Hematol Oncol"},{"issue":"5","key":"2025081313414483500_bib248","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00247-014-3209-4","article-title":"Outcomes in children with deep vein thrombosis managed with percutaneous endovascular thrombolysis","volume":"45","author":"Dandoy","year":"2015","journal-title":"Pediatr Radiol"},{"issue":"4","key":"2025081313414483500_bib249","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jvir.2015.12.753","article-title":"Endovascular thrombolysis in the management of iliofemoral thrombosis in children: a multi-institutional experience","volume":"27","author":"Gaballah","year":"2016","journal-title":"J Vasc Interv Radiol"},{"issue":"8","key":"2025081313414483500_bib250","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.jvir.2014.04.003","article-title":"Endovascular venous thrombolysis in children younger than 24 months","volume":"25","author":"Kukreja","year":"2014","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"2025081313414483500_bib251","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s11239-015-1209-3","article-title":"Endovascular thrombolysis to salvage central venous access in children with catheter-associated upper extremity deep vein thrombosis: technique and initial results","volume":"40","author":"Lungren","year":"2015","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"2025081313414483500_bib252","doi-asserted-by":"crossref","first-page":"e28144","DOI":"10.1002\/pbc.28144","article-title":"Catheter-directed thrombolysis for submassive pulmonary embolism in children: a case series","volume":"67","author":"Belsky","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2025081313414483500_bib253","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1067\/mpd.2001.118428","article-title":"Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children","volume":"139","author":"Gupta","year":"2001","journal-title":"J Pediatr"},{"issue":"4","key":"2025081313414483500_bib254","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/MPH.0b013e318047b78b","article-title":"Assessing the outcome of systemic tissue plasminogen activator for the management of venous and arterial thrombosis in pediatrics","volume":"29","author":"Newall","year":"2007","journal-title":"J Pediatr Hematol Oncol"},{"key":"2025081313414483500_bib255","volume-title":"StatPearls","author":"Hughes","year":"2023"},{"issue":"3","key":"2025081313414483500_bib256","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1051-0443(07)61418-3","article-title":"Alteplase as an alternative to urokinase. Advisory panel on catheter-directed thrombolytic therapy","volume":"11","author":"Semba","year":"2000","journal-title":"J Vasc Interv Radiol"},{"key":"2025081313414483500_bib258","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jclinepi.2016.09.009","article-title":"GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT","volume":"81","author":"Sch\u00fcnemann","year":"2017","journal-title":"J Clin Epidemiol"},{"issue":"14","key":"2025081313414483500_bib1","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1182\/bloodadvances.2023009723","article-title":"The value of the old and the new","volume":"7","author":"Monagle","year":"2023","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/10\/2587\/2376568\/blooda_adv-2024-015328-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/10\/2587\/2376568\/blooda_adv-2024-015328-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T17:42:21Z","timestamp":1755106941000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/10\/2587\/537455\/American-Society-of-Hematology-International"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":258,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,5,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015328","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5,27]]},"published":{"date-parts":[[2025,5,27]]}}}